BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21506895)

  • 1. New targeted therapies for renal cell carcinoma.
    Fisher R; Pickering L; Larkin J
    Expert Opin Investig Drugs; 2011 Jul; 20(7):933-45. PubMed ID: 21506895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
    Kirkali Z
    BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for renal cell carcinoma.
    Varella L; Rini BI
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):343-53. PubMed ID: 20443750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of metastatic renal cell carcinoma in the era of targeted therapies.
    Webber K; Cooper A; Kleiven H; Yip D; Goldstein D
    Intern Med J; 2011 Aug; 41(8):594-605. PubMed ID: 21627746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
    Oudard S; Elaidi RT
    Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and contrasts of the development of tivozanib for therapy of kidney cancer.
    Gupta S; Fishman M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2915-22. PubMed ID: 22098229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies in bone sarcomas: current approach and future directions.
    Yarber JL; Agulnik M
    Expert Opin Investig Drugs; 2011 Jul; 20(7):973-9. PubMed ID: 21510829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging drugs for renal cell carcinoma.
    Shaheen PE; Bukowski RM
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):773-95. PubMed ID: 16262562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.
    Tan TH; Pranavan G; Haxhimolla HZ; Yip D
    Asia Pac J Clin Oncol; 2010 Mar; 6(1):5-18. PubMed ID: 20398033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is new in kidney cancer?
    Kirkali Z
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1753-5. PubMed ID: 19954286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytokine-based and targeted therapy of metastatic renal cell carcinoma--a current analysis].
    Johannsen M; Ringsdorf M; Römer A; Loening SA; Roigas J
    Aktuelle Urol; 2007 Jan; 38(1):38-45. PubMed ID: 17290328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of response to targeted therapy in renal cell carcinoma.
    Eisengart LJ; MacVicar GR; Yang XJ
    Arch Pathol Lab Med; 2012 May; 136(5):490-5. PubMed ID: 22229848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on novel agents in renal cell carcinoma.
    Tamaskar I; Pili R
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1817-27. PubMed ID: 19954293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma.
    Rathmell WK; Martz CA; Rini BI
    Curr Opin Oncol; 2007 May; 19(3):234-40. PubMed ID: 17414642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
    Wright I; Kapoor A
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel agents and approaches for advanced renal cell carcinoma.
    Figlin R; Sternberg C; Wood CG
    J Urol; 2012 Sep; 188(3):707-15. PubMed ID: 22818130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.